Importantly, stronger immunoreactivity of SLC52A3a in nucleus was significantly associated with poor prognosis of ESCC patients (P = 0.003), while its expression in cytoplasmic was not prognostic (P = 0.079) (Fig. 3a, b). This evidence concerns the gene SLC52A3 and esophageal squamous cell carcinoma.